Categories
BLOG

project cbd report

Special Reports

Periodically, Project CBD publishes special, in-depth reports on important topics in cannabis and CBD science.

Special Report on Synthetic Cannabinoids & Vaping-Related Lung Injuries

An extensive review of the scientific literature by Project CBD has found that the CDC ’s diagnostic criteria for confirmed cases in the ongoing vaping-related outbreak parallels the symptoms of pulmonary injury associated with the use of “synthetic cannabinoids,” a group of difficult-to-detect research compounds that powerfully influence the endocannabinoid system ( ECS ).

CBD Survey Results: Cultivating Wellness

In early 2019 Project CBD began collecting responses to a survey we designed to figure out who is using CBD , how and why people are using CBD , what kinds of products they are consuming, and whether or not CBD is working for them. The analysis in this report covers an eight-month period and encompasses over 3500 responses.

Comments to the Food and Drug Administration on CBD and Cannabis

In July 2019 Project CBD submitted comments to the FDA regarding the regulation of CBD and cannabis. This report represents a comprehensive response to the FDA ’s inquiry and includes a regulatory framework for cannabis and other traditional herbal medicinal products.

Educational Primer on Cannabinoid-Drug Interactions

Given the increasing acceptance and prevalence of cannabis as a therapeutic option, it’s important for physicians and patients to understand how various cannabis components interact with commonly consumed pharmaceuticals. Project CBD has published an in-depth primer on Cannabinoid-Drug Interactions for health professionals, patients, and public policy-makers. The 33-page report is available for free download.

Handout on Cannabis & Opiates

This handout explores the staggering scope of opioid abuse in America, and a neglected treatment option for opioid addiction: medical cannabis.

Green Rush Blues: California Cannabis After Legalization

This three part series takes a deep dive into the impact of California’s cannabis regulations.

Project CBD Responds to California’s Proposed Testing Requirements

Project CBD critiques California’s proposed regulations for cannabis testing regarding pesticides, heavy metals, and solvents and makes recommendations for amending them.

Cannabis in the Treatment of Age-Related Pain

This survey—a collaboration between Care By Design and Project CBD —sought to answer several questions: How satisfied are patients with cannabis as an analgesic? How does medical marijuana compare to other pain management approaches, in particular, opiates? How do the most common pain management therapies compare in terms of their impact on quality of life? Eight hundred people, most between 50 to 70 years old, responded to the survey. Over 80 percent reported that they were suffering from chronic pain; close to half reported suffering from acute pain. A significant decrease in opiate usage among elderly patients on cannabis therapy was the study’s most notable finding.

Cannabis in the Treatment of PTSD

Between seven and eight percent of people will develop PTSD (Post-Traumatic Stress Disorder) in their lifetime. Among military veterans, the rates are higher. Care By Design recently surveyed 300 patients on their use of cannabis and other medications to treat PTSD . The survey asked what medications patients had been prescribed for their PTSD -related symptoms and what impact these medications—and cannabis—had on five telltale symptoms of PTSD : anxiety, depression, pain, anger or irritability, and sleep problems.

First Ever Survey of CBD Use

Care By Design surveyed thousands of patients who had been using CBD -rich cannabis medicines for over 30 days. They asked patients what they were taking CBD -rich cannabis for, the ratio of CBD -to- THC they were using, and about its impact on pain, discomfort, energy, mood, and overall wellbeing.

Explore our in-depth Special Reports on important topics in cannabis and CBD science.

Medical Marijuana, Inc. v. ProjectCBD.com

The Project CBD defendants, ProjectCBD.com, website founder Martin Lee, and article author Aaron Cantu, appealed a trial court’s order denying their special motion to strike the three causes of action asserted in the second amended complaint. The Project CBD defendants contended the trial court erred in denying their motion because the plaintiffs failed to demonstrate a probability of prevailing on their claims. This case arose from the publication of an article regarding the safety of a cannabidiol (CBD) product, Real Scientific Hemp Oil (RSHO), sold by plaintiffs Medical Marijuana, Inc. (MMI) and HempMeds PX, LLC (HempMeds) (jointly the plaintiffs). The plaintiffs contended the article contained false information about RSHO and that the named defendants who were involved in the publication of the article, should be held liable for libel, false light, and unfair competition due to their publication of the article. After review, the Court of Appeal concluded the trial court erred in determining that the plaintiffs demonstrated a probability of prevailing on the merits of their claims. The Court therefore reversed the trial court’s order and remanded the matter with directions to enter an order granting the Project CBD defendants’ anti-SLAPP motion.

Disclaimer: Justia Annotations is a forum for attorneys to summarize, comment on, and analyze case law published on our site. Justia makes no guarantees or warranties that the annotations are accurate or reflect the current state of law, and no annotation is intended to be, nor should it be construed as, legal advice. Contacting Justia or any attorney through this site, via web form, email, or otherwise, does not create an attorney-client relationship.

The Project CBD defendants, ProjectCBD.com, website founder Martin Lee, and article author Aaron Cantu, appealed a trial court's order denying their special motion to strike the three causes of action asserted in the second amended complaint. The Project CBD defendants contended the trial court erred in denying their motion because the plaintiffs failed to demonstrate a probability of prevailing on their claims. This case arose from the publication of an article regarding the safety of a cannabidiol (CBD) product, Real Scientific Hemp Oil (RSHO), sold by plaintiffs Medical Marijuana, Inc. (MMI) and HempMeds PX, LLC (HempMeds) (jointly the plaintiffs). The plaintiffs contended the article contained false information about RSHO and that the named defendants who were involved in the publication of the article, should be held liable for libel, false light, and unfair competition due to their publication of the article. After review, the Court of Appeal concluded the trial court erred in determining that the plaintiffs demonstrated a probability of prevailing on the merits of their claims. The Court therefore reversed the trial court's order and remanded the matter with directions to enter an order granting the Project CBD defendants' anti-SLAPP motion. ]]>